Contineum Therapeutics, Inc. (CTNM)

Market Cap	322.17M
Revenue (ttm)	n/a
Net Income (ttm)	-59.39M
Shares Out	29.18M
EPS (ttm)	-2.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,028
Open	11.02
Previous Close	10.98
Day's Range	10.89 - 11.05
52-Week Range	3.35 - 15.25
Beta	n/a
Analysts	Strong Buy
Price Target	20.00 (+81.16%)
Earnings Date	Oct 30, 2025

About CTNM

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 5, 2024
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: CTNM
• Website: https://www.contineum-tx.com

Analyst Summary

According to 5 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 81.16% from the latest price.

Price Target

$20.0

(81.16% upside)

Analyst Consensus: Strong Buy